Simulations Plus Announces Further Success in Malaria Drug Design Project

Published: Apr 11, 2012

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of consulting services and software for pharmaceutical discovery and development, today announced that further testing shows that the newest molecule the Company has designed to inhibit the malaria parasite is nearly three times more potent as an inhibitor of the drug-sensitive 3D7 strain of the malaria parasite than its best previous molecule. In addition, this newest molecule shows nanomolar activity against three drug-resistant strains of the malaria parasite. The term nanomolar activity refers to a concentration expressed in billionths of a mole per liter of fluid needed to inhibit 50% (“IC50”) of the parasites in a laboratory experiment. Typical drug IC50s run from millimolar (1/1000 of a mole per liter of fluid) for less potent drugs to less than 1 nanomolar for extremely potent drugs. The smaller the IC50, the smaller the amount of drug needed to have a therapeutic effect.

Back to news